Siemens Healthineers Lifts Guidance Again on Covid-19 Test Demand
04 May 2022 - 3:41PM
Dow Jones News
By Cristina Roca
Siemens Healthineers AG said Wednesday that second-quarter
earnings rose, and raised its guidance again on the back of strong
demand for rapid Covid-19 tests.
The German medical-equipment maker reported net income of 579
million euros ($609.1 million) in the quarter ended March 31,
compared with EUR443 million a year earlier.
Revenue was EUR5.46 billion, up 38% on a reported basis
following the integration of the recently acquired Varian business.
It rose 16% on a comparable basis. Analysts had expected revenue of
EUR5.25 billion, according to a Vara consensus estimate.
High demand for rapid Covid-19 antigen tests at the diagnostics
segment was the main driver of the rise in revenue, but all
divisions contributed to growth, Siemens Healthineers said.
The company said it now expects revenue from rapid Covid-19
tests to come in at around EUR1.3 billion for fiscal 2022, from
previous expectations of around EUR700 million.
As a result, it raised its full-year guidance and now expects
annual comparable revenue growth of 5.5%-7.5%, from 3%-5%
previously, and adjusted basic earnings per share of
EUR2.25-EUR2.35, from previous views of EUR2.18-EUR2.30.
The company had already lifted its full-year view during
first-quarter reporting in February, also on the back of Covid-19
testing demand.
Write to Cristina Roca at cristina.roca@wsj.com
(END) Dow Jones Newswires
May 04, 2022 01:26 ET (05:26 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Siemens Healthineers (TG:SHL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Siemens Healthineers (TG:SHL)
Historical Stock Chart
From Apr 2023 to Apr 2024